当前位置:
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
时间:2024-06-29 04:51:37 阅读(143)
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg.
According to the company’s press statement, the approval has been granted to market a generic equivalent of Qtern Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India.
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT November 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Adani raises $15 billion in equity, debt in comeback strategy after Hindenburg rout
- Will Nifty snap its gaining streak or cross 17,700- Check 8 things to know before market opens on 11 April
- Will Nifty reclaim 18300 or fall in trade- Check US shares, Asian markets, FII activity, SGX Nifty, more
- Yamuna on edge! Evacuation begins as water level breaches danger mark – See Photos
- Adani Enterprises withdraws FPO worth Rs 20,000 Crore; money to be returned to investors
- Adani Enterprises to be dropped from Dow Jones sustainability indices
- Will Nifty continue its winning streak to trade above 19000- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- 2023 could be a year of earnings downgrades- Christopher Wood
- Adani Group stocks rise, four hit upper circuit after major block deal; SC sets up panel to probe stock crash